Table 2.

Summary of current or recently completed clinical trials of BNCT for the treatment of glioblastoma

FacilityNo. patientsDuration of administrationDrugDose (mg/kg)Boron concentration* (μg 10B/g)Estimated peak normal brain dose [Gy(w)]Average normal brain dose [Gy(w)]Reference
HTR, Musashi Institute of Technology, JRR, Kyoto University research reactor, Japan>200 (1968)1 hBSH100∼20-3015 Gy 10B componentND(157, 158)
High Flux Reactor, Petten, the Netherlands26 (1997-present)100 mg/kg/minBSH100308.6-11.4 Gy§ 10B componentND(166)
LVR-15, Rez, Czech Republic5 (2001-present)1 hBSH100∼20-30<14.2<2(167)
Brookhaven Medical Research reactor, Brookhaven, United States53 (1994-1999)2 hBPA250-33012-168.4-14.81.8-8.5(141, 168)
MITR-II, M67 MIT, United States20 (1996-1999)1-1.5 hBPA250-35010-128.7-16.43.0-7.4(165)
MITR-II, FCB MIT, United States6 (2001-present)1.5 hBPA350∼15Unpublished
Studsvik AB Sweden17 (30) (2001-present)6 hBPA90024 (range, 15-34)7.3-15.53.6-6.1(130)
FiR1, Helsinki Finland18 (1999-present) protocol P-012 hBPA290-40012-158-13.53-6 <7(131)
FiR1, Helsinki Finland3 (2001-present)** protocol P-032 hBPA29012-15<82-3 <6(131)
  • * During the irradiation.

  • 10B physical dose component dose to a point 2 cm deeper than the air-filled tumor cavity.

  • Four fractions, each with a BSH infusion, 100 mg/kg the first day, enough to keep the average blood concentration at 30 μg 10B/g during treatment on days 2 to 4.

  • § 10B physical dose component at the depth of the thermal neutron fluence maximum.

  • Includes two i.c. melanomas.

  • J. Capala, personal communication.

  • ** Retreatment protocol for recurrent glioblastoma.